Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Circulating biomarkers in patients with glioblastoma.

Müller Bark J, Kulasinghe A, Chua B, Day BW, Punyadeera C.

Br J Cancer. 2019 Oct 31. doi: 10.1038/s41416-019-0603-6. [Epub ahead of print] Review.

PMID:
31666668
2.

The emerging clinical potential of circulating extracellular vesicles for non-invasive glioma diagnosis and disease monitoring.

Hallal S, Ebrahimkhani S, Shivalingam B, Graeber MB, Kaufman KL, Buckland ME.

Brain Tumor Pathol. 2019 Apr;36(2):29-39. doi: 10.1007/s10014-019-00335-0. Epub 2019 Mar 11. Review.

PMID:
30859343
3.

Emerging circulating biomarkers in glioblastoma: promises and challenges.

Touat M, Duran-Peña A, Alentorn A, Lacroix L, Massard C, Idbaih A.

Expert Rev Mol Diagn. 2015;15(10):1311-23. doi: 10.1586/14737159.2015.1087315. Review.

4.

Circulating biomarkers for gliomas.

Westphal M, Lamszus K.

Nat Rev Neurol. 2015 Oct;11(10):556-66. doi: 10.1038/nrneurol.2015.171. Epub 2015 Sep 15. Review.

PMID:
26369507
5.

Significance of liquid biopsy in glioblastoma - A review.

Klekner Á, Szivos L, Virga J, Árkosy P, Bognár L, Birkó Z, Nagy B.

J Biotechnol. 2019 Jun 10;298:82-87. doi: 10.1016/j.jbiotec.2019.04.011. Epub 2019 Apr 12.

PMID:
30986516
6.

Blood-based biomarkers for the diagnosis and monitoring of gliomas.

Zachariah MA, Oliveira-Costa JP, Carter BS, Stott SL, Nahed BV.

Neuro Oncol. 2018 Aug 2;20(9):1155-1161. doi: 10.1093/neuonc/noy074. Review.

7.

Comprehensive proteome profiling of glioblastoma-derived extracellular vesicles identifies markers for more aggressive disease.

Mallawaaratchy DM, Hallal S, Russell B, Ly L, Ebrahimkhani S, Wei H, Christopherson RI, Buckland ME, Kaufman KL.

J Neurooncol. 2017 Jan;131(2):233-244. doi: 10.1007/s11060-016-2298-3. Epub 2016 Oct 21.

8.

Liquid biopsies in patients with diffuse glioma.

Best MG, Sol N, Zijl S, Reijneveld JC, Wesseling P, Wurdinger T.

Acta Neuropathol. 2015 Jun;129(6):849-65. doi: 10.1007/s00401-015-1399-y. Epub 2015 Feb 27.

9.

Preoperative biomarkers of tumour vascularity are elevated in patients with glioblastoma multiforme.

Bennett IE, Guo H, Kountouri N, D'abaco GM, Hovens CM, Moffat BA, Desmond P, Drummond K, Kaye AH, Morokoff AP.

J Clin Neurosci. 2015 Nov;22(11):1802-8. doi: 10.1016/j.jocn.2015.06.013. Epub 2015 Aug 22.

PMID:
26308396
10.

Tumour progression or pseudoprogression? A review of post-treatment radiological appearances of glioblastoma.

Abdulla S, Saada J, Johnson G, Jefferies S, Ajithkumar T.

Clin Radiol. 2015 Nov;70(11):1299-312. doi: 10.1016/j.crad.2015.06.096. Epub 2015 Aug 10. Review.

PMID:
26272530
11.

Liquid biopsy for brain tumors.

Shankar GM, Balaj L, Stott SL, Nahed B, Carter BS.

Expert Rev Mol Diagn. 2017 Oct;17(10):943-947. doi: 10.1080/14737159.2017.1374854. Epub 2017 Sep 6. Review.

12.

Circulating tumour DNA, microRNA and metabolites in cerebrospinal fluid as biomarkers for central nervous system malignancies.

Zorofchian S, Iqbal F, Rao M, Aung PP, Esquenazi Y, Ballester LY.

J Clin Pathol. 2019 Apr;72(4):271-280. doi: 10.1136/jclinpath-2018-205414. Epub 2018 Nov 22. Review.

PMID:
30467241
13.

Current status of liquid biopsies for the detection and management of prostate cancer.

Lu YT, Delijani K, Mecum A, Goldkorn A.

Cancer Manag Res. 2019 Jun 6;11:5271-5291. doi: 10.2147/CMAR.S170380. eCollection 2019. Review.

14.

Advanced MRI Techniques in the Monitoring of Treatment of Gliomas.

Hyare H, Thust S, Rees J.

Curr Treat Options Neurol. 2017 Mar;19(3):11. doi: 10.1007/s11940-017-0445-6. Review.

PMID:
28349351
15.

Integrating liquid biopsies into the management of cancer.

Siravegna G, Marsoni S, Siena S, Bardelli A.

Nat Rev Clin Oncol. 2017 Sep;14(9):531-548. doi: 10.1038/nrclinonc.2017.14. Epub 2017 Mar 2. Review.

PMID:
28252003
16.

Potential clinical role of telomere length in human glioblastoma.

La Torre D, Aguennouz M, Conti A, Giusa M, Raffa G, Abbritti RV, Germano' A, Angileri FF.

Transl Med UniSa. 2011 Oct 17;1:243-70. Print 2011 Sep.

17.

Opportunities and challenges of circulating biomarkers in neuroblastoma.

Trigg RM, Shaw JA, Turner SD.

Open Biol. 2019 May 31;9(5):190056. doi: 10.1098/rsob.190056.

18.

Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma.

Simon T, Pinioti S, Schellenberger P, Rajeeve V, Wendler F, Cutillas PR, King A, Stebbing J, Giamas G.

Mol Cancer. 2018 Aug 31;17(1):132. doi: 10.1186/s12943-018-0878-x.

19.

Glioblastoma biomarkers from bench to bedside: advances and challenges.

Farias-Eisner G, Bank AM, Hwang BY, Appelboom G, Piazza MA, Bruce SS, Sander Connolly E.

Br J Neurosurg. 2012 Apr;26(2):189-94. doi: 10.3109/02688697.2011.629698. Epub 2011 Dec 17. Review.

PMID:
22176646
20.

Glioblastoma extracellular vesicles: reservoirs of potential biomarkers.

Redzic JS, Ung TH, Graner MW.

Pharmgenomics Pers Med. 2014 Feb 13;7:65-77. doi: 10.2147/PGPM.S39768. eCollection 2014. Review.

Supplemental Content

Support Center